ZimVie Inc. (NASDAQ:ZIMV) Stake Cut by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. cut its position in shares of ZimVie Inc. (NASDAQ:ZIMV - Free Report) by 16.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 332,182 shares of the company's stock after selling 66,124 shares during the quarter. Jacobs Levy Equity Management Inc. owned 1.20% of ZimVie worth $4,634,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. SG Americas Securities LLC increased its position in shares of ZimVie by 15.7% during the 4th quarter. SG Americas Securities LLC now owns 11,110 shares of the company's stock valued at $155,000 after purchasing an additional 1,508 shares during the period. EMC Capital Management increased its position in shares of ZimVie by 47.0% during the 4th quarter. EMC Capital Management now owns 13,802 shares of the company's stock valued at $193,000 after purchasing an additional 4,414 shares during the period. Wells Fargo & Company MN increased its position in shares of ZimVie by 17.8% during the 4th quarter. Wells Fargo & Company MN now owns 17,037 shares of the company's stock valued at $238,000 after purchasing an additional 2,569 shares during the period. Integrated Quantitative Investments LLC acquired a new position in shares of ZimVie during the 4th quarter valued at $248,000. Finally, Principal Financial Group Inc. increased its position in shares of ZimVie by 9.8% during the 4th quarter. Principal Financial Group Inc. now owns 19,054 shares of the company's stock valued at $266,000 after purchasing an additional 1,702 shares during the period. 95.63% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on ZIMV. UBS Group lowered their price target on ZimVie from $16.00 to $10.00 and set a "neutral" rating on the stock in a research report on Thursday, May 15th. B. Riley started coverage on ZimVie in a report on Thursday, April 10th. They issued a "buy" rating and a $16.00 target price on the stock. Finally, Needham & Company LLC restated a "hold" rating on shares of ZimVie in a report on Wednesday, April 9th.

ZimVie Price Performance

Shares of NASDAQ ZIMV traded down $0.04 during mid-day trading on Tuesday, reaching $8.72. The company had a trading volume of 21,512 shares, compared to its average volume of 213,581. The company has a current ratio of 1.94, a quick ratio of 1.38 and a debt-to-equity ratio of 0.57. The stock has a market cap of $242.69 million, a PE ratio of -0.66 and a beta of 2.16. The company has a 50-day moving average price of $9.87 and a two-hundred day moving average price of $12.42. ZimVie Inc. has a 1-year low of $8.55 and a 1-year high of $22.40.

ZimVie (NASDAQ:ZIMV - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.27 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.21 by $0.06. The business had revenue of $112.00 million for the quarter, compared to analysts' expectations of $113.10 million. ZimVie had a positive return on equity of 2.90% and a negative net margin of 77.31%. On average, equities analysts anticipate that ZimVie Inc. will post 0.6 earnings per share for the current year.

ZimVie Company Profile

ZimVie Inc, together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment.